[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-ercp-pancreatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-ercp-pancreatitis":56},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,76,107,131,153,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100644855","ice-cold-water-flushing-of-the-ampulla-after-endoscopic-sphincterotomy-to-reduce-post-ercp-pancreatitis-100644855",false,"NCT07677397","Ice Cold Water Flushing of the Ampulla After Endoscopic Sphincterotomy to Reduce Post-ERCP Pancreatitis","A Multicenter Randomized Controlled Trial of Ice Cold Water Flushing of the Ampulla After Endoscopic Sphincterotomy to Reduce Post-ERCP Pancreatitis","ERCP","Inclusion Criteria:\n\n* All adults (agesld 18 years old) scheduled for an endoscopic sphincterotomy at the participating hospitals.\n\nExclusion Criteria:\n\n* Patients with missing data, acute or chronic pancreatitis, pancreatic cancer, or those unable to provide informed consent.","ALL","18 Years",{"count":20,"type":21},210,"ESTIMATED","INTERVENTIONAL",[24],"NA","Endoscopic retrograde cholangiopancreatography (ERCP) is an essential diagnostic and therapeutic tool used to manage diseases of the pancreatic and biliary systems. During the procedure, an upper endoscope is used to reach the major duodenal papilla, and a contrast material is injected into the ducts for radiologic imaging. In an endoscopic sphincterotomy, a specialized knife cuts the biliary sphincter to treat papilla conditions or facilitate therapeutic interventions.\n\nThe most common complication following an ERCP is pancreatitis, carrying an incidence rate of 3.5% to 9.7%. Standard preventive strategies currently include careful patient selection, rectal administration of NSAIDs (like indomethacin or diclofenac), aggressive intravenous hydration, and pancreatic stent placement.\n\nThe Innovation: Flushing the ampulla with ice-cold water after a sphincterotomy is a safe,easy, and cost-effective evolving intervention. While initial data demonstrates its safety,there is a clear deficiency in multicenter randomized trials assessing its overall clinical effectiveness, and no such studies have been conducted in the Gulf region. The primary goal of this study is to evaluate the effectiveness of ice-cold water flushing ofthe ampulla after endoscopic sphincterotomy in reducing the incidence of post-ERCP pancreatitis.",[27],"Post ERCP Pancreatitis","NOT_YET_RECRUITING","2026-06-27",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":21},"2026-06-28",{"date":36,"type":21},"2027-06-30",{"name":38,"class":39},"Oman Ministry of Health","OTHER_GOV",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":51,"conditions":52,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100641543","phase-4-indomethacin-for-biliary-ercp-patients-100641543","NCT07661498","Indomethacin for Biliary ERCP Patients","Indomethacin vs. no Indomethacin for Patients Undergoing Biliary ERCP With Prior Biliary Sphincterotomy","Inclusion Criteria:\n\n1. Male or female ≥ 18 years of age at the time of ERCP.\n2. Scheduled to undergo routine biliary ERCP with documentation of a prior biliary sphincterotomy.\n3. Ability to receive rectal medication.\n4. Ability and willingness to comply with all study procedures and follow-up requirements.\n5. Written informed consent (and assent when applicable) was obtained from the subject or the subject's legal representative, and the subject's ability to comply with the requirements of the study was confirmed.\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.\n2. Known hypersensitivity or contraindication to indomethacin, other nonsteroidal anti-inflammatory drugs, or suppository components.\n3. Active gastrointestinal bleeding, history of NSAID-induced gastrointestinal ulceration, or other conditions that contraindicate NSAID use.\n4. Significant renal impairment (e.g., baseline serum creatinine above institutional upper limit of normal or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n5. Current use of other NSAIDs that cannot be safely discontinued per the investigator's judgment.\n6. Known chronic pancreatitis\n7. Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.",{"count":48,"type":21},860,[50],"PHASE4","This study is a randomized clinical trial evaluating the efficacy of rectal indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in patients undergoing biliary ERCP who have a history of prior biliary sphincterotomy. While rectal indomethacin has demonstrated benefits in preventing post-ERCP pancreatitis in high-risk patients, its utility in this specific patient subgroup remains unclear. This trial aims to determine whether prophylactic administration of indomethacin offers a measurable benefit over no intervention in this lower-risk population.\n\nEligible patients will be identified prior to their scheduled biliary ERCP and screened for inclusion criteria. Following informed consent, participants will be randomized to receive either rectal indomethacin or no indomethacin prior to the procedure.",[53,54,55,56,57,58],"Pancreatitis Biliary","Pancreatitis Acute Biliary","Pancreatitis","Post-ERCP Pancreatitis","Post-ERCP Acute Pancreatitis","Post-ERCP Adverse Events",[15,60,61,62,63,64],"pancreatitis","post-ERCP pancreatitis","PEP","pancreatitis acute biliary","post-ERCP adverse events","2026-06-16",{"date":67,"type":32},"2026-06-22",{"date":69,"type":21},"2026-07",{"date":71,"type":21},"2031-07",{"name":73,"class":74},"University of California, San Francisco","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":75},"100619572","spontaneous-dislocation-and-adverse-events-of-a-prophylactic-pancreatic-stent-100619572","NCT07346365","Spontaneous Dislocation and Adverse Events of a Prophylactic Pancreatic Stent","Spontaneous Dislocation and Adverse Events of a Prophylactic Pancreatic Stent: a Prospective, Randomised, Multicenter Study (SAFE PANCREAS)","SAFE PANCREAS","Inclusion Criteria:\n\n* prophylactic pancreatic stent (5Fr 4cm length)\n* informed consent\n\nExclusion Criteria:\n\n* necrotising post-ercp-pancreatitis\n* pregnancy\u002Fbreastfeeding\n* Billroth II",{"count":85,"type":21},358,[24],"A multicenter, prospective, controlled randomized study to investigate the optimal duration of protective pancreatic stents after endoscopic retrograde cholangiopancreatography (ERCP).\n\nThe primary endpoint is the complication rate that can be clinically attributed to the remaining pancreatic prosthesis or its removal in the study groups. Secondary endpoints are spontaneous removal of the pancreatic stent, length of hospital stay, rate of follow-up examinations per group, influencing factors, and a possible exploratory analysis.",[89,15,90,56,91],"Stent Dislodgement","Pancreas Stent","Prophylactic Pancreatic Stent",[93,94,95,96,97,62],"ercp","prophylactic pancreatic stent","post-ercp-pancreatitis","pancreatic stent","post-ercp pancreatitis","2026-01-14",{"date":100,"type":32},"2026-01-16",{"date":102,"type":21},"2026-01-01",{"date":104,"type":21},"2032-06",{"name":106,"class":74},"Johann Wolfgang Goethe University Hospital",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":75},"100611984","phase-4-dose-escalation-of-rectal-indomethacin-for-preventing-pep-100611984","NCT07247682","Dose-escalation of Rectal Indomethacin for Preventing PEP","Dose-escalation of Rectal Indomethacin for Post-ERCP Pancreatitis Prevention in High-risk Patients: Protocol of a Multicentre Randomised Clinical Trial","Inclusion Criteria:Participants will be eligible for enrollment if they meet all of the following criteria: 1. age over 18 years; 2. classified as high risk for post-ERCP pancreatitis; 3. provision of signed, written informed consent.\n\nExclusion Criteria:Participants will be excluded if they meet any of the following conditions: 1. inaccessible major papilla; 2. surgically altered gastrointestinal anatomy; 3. current diagnosis of acute pancreatitis; 4. placement of a pancreatic stent; 5. contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs), including known allergy, renal insufficiency, or active peptic ulcer disease; 6. anticipated low risk of post-ERCP pancreatitis (e.g., patients with chronic calcific pancreatitis, pancreatic head mass, or those undergoing biliary interventions through a pre-existing sphincterotomy); 7.severe active cardiopulmonary disease; 8. pregnancy or breastfeeding; 9. presence of an ampullary tumor.\n\n\\-",true,{"count":116,"type":21},1036,[50],"Our aim is to compare the efficacy of 100 mg versus 200 mg rectal indometacin in preventing post-ERCP pancreatitis (PEP) among high-risk patients without no pancreatic stenting. The 100 mg versus 200 mg indometacin trial is a multicentre, single-blind, randomized controlled study. High-risk patients for PEP without pancreatic stent insertion will be informed about the opportunity to participate. A total of 1,036 eligible patients will be randomly assigned in a 1:1 ratio to one of two groups: (1) administration of 100 mg rectal indometacin immediately after ERCP (standard-dose group), or (2) administration of 200 mg rectal indometacin immediately after ERCP (high-dose group). The primary outcome is the incidence and severity of PEP. Secondary outcomes include hyperamylasemia and other ERCP-related adverse events (AEs).",[56],[61,121,15],"indometacin","2025-11-18",{"date":124,"type":32},"2025-11-25",{"date":126,"type":21},"2025-12-01",{"date":128,"type":21},"2028-12-30",{"name":130,"class":74},"The First Affiliated Hospital of Anhui Medical University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100599766","phase-4-low-dose-vs-standard-dose-indomethacin-for-preventing-post-ercp-pancreatitis-100599766","NCT07088757","Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis","Low-Dose Versus Standard-Dose Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Multicentre, Non-Inferiority, Double-Blind, Randomised, Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Patients planned to undergo Endoscopic Retrograde Cholangiopancreatography\n\nExclusion Criteria:\n\n* Standard contraindications to ERCP\n* Allergy to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)\n* Use of NSAIDs within 7 days prior to ERCP\n* Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction \\[Cr \\>1.4mg\u002Fdl=120umol\u002Fl\\]; presence of coagulopathy before the procedure)\n* Acute pancreatitis within 3 days before ERCP\n* Hemodynamic instability\n* Pregnancy or lactation\n* Patients who are unwilling or unable to provide informed consent",{"count":139,"type":21},1366,[50],"Endoscopic Retrograde Cholangiopancreatography (ERCP) is a widely used procedure for diagnosing and treating pancreatic and biliary diseases. Despite its benefits, ERCP carries a risk of post-procedure pancreatitis (PEP), which occurs in approximately 12.2% of cases and can significantly increase healthcare costs and patient morbidity. Preventing PEP is crucial for improving patient outcomes and reducing the economic burden of ERCP.\n\nNonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, have been shown to be effective in reducing the incidence of PEP when administered rectally before ERCP. The standard dose recommended by guidelines is 100mg, which has been associated with a significant reduction in PEP rates. However, higher doses of NSAIDs can increase the risk of adverse events, including gastrointestinal bleeding and renal impairment. Therefore, there is a need to determine whether a lower dose can provide similar benefits without increasing these risks.\n\nThis multicenter, non-inferiority, double-blind, randomized controlled trial will be conducted in China. Participants will be adults aged 18 or older scheduled for ERCP. They will be randomly assigned in a 1:1 ratio to either the low-dose (50mg) or standard-dose (100mg) indomethacin group. The intervention will be administered rectally 30 minutes before the ERCP procedure. The study will follow a double-blind design, ensuring that both patients and investigators are unaware of the treatment allocation.\n\nThe results of this trial could significantly influence clinical practice by providing evidence on the effectiveness of a lower dose of indomethacin in preventing PEP. This could lead to a reduction in the risk of adverse events associated with higher doses and potentially decrease healthcare costs without compromising patient safety. By optimizing the dosing of indomethacin, this study aims to improve the safety and cost-effectiveness of ERCP procedures.",[56],"RECRUITING","2025-11-16",{"date":122,"type":32},{"date":147,"type":32},"2025-09-15",{"date":149,"type":21},"2026-12-01",{"name":151,"class":74},"Changhai Hospital",12,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},"100535359","early-pancreatic-stent-placement-for-preventing-pep-100535359","NCT06250803","Early Pancreatic Stent Placement for Preventing PEP","Early Versus Late Pancreatic Stent Placement for Preventing Post-ERCP Pancreatitis: a Multicentre, Randomised Trial","EVL","Inclusion Criteria:\n\nParticipants who fulfill all the below criteria will be enrolled: 1. with naive papilla; 2. over 18 years; 3. undergoing ERCP with pancreatic guidewire-assisted technique for biliary access; 4. providing a signed, written informed consent.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded: 1. unreachable main papillae; 2. surgically altered gastrointestinal anatomy; 3. concurrent acute pancreatitis; 4. biliary cannulation over pancreatic duct stent after precut sphincterotomy or wire-guided method (native early attribute); 5. failed biliary cannulation; 6. severe active cardiopulmonary disease; 7. breastfeeding or pregnancy; 8. ampullary tumour.",{"count":162,"type":21},768,[24],"Our aim is to compare early versus late pancreatic stent placement in preventing PEP among patients with naive papilla. The EVL trial will provide essential answers regarding the optimal timing of prophylactic pancreatic stent placement in PEP prevention.All patients with difficult biliary cannulation undergoing endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic guidewire-assisted technique for biliary access will be told about the opportunity to participate in EVL research. In total, 768 patients will be randomly assigned (1:1) to two arms: (1) early pancreatic stent placement (EPSP) (a pancreatic stent will be placed immediately after endoscopic retrograde cholangiography (ERC) or endoscopic sphincterotomy (EST)) and (2) late pancreatic stent placement (LPSP) (a pancreatic stent will be placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage).The primary outcome is the rate and severity of PEP. The secondary outcomes are hyperamylasemia, the rate of stenting success, and other ERCP-related adverse events (AEs).",[166,56],"Cholangiopancreatography, Endoscopic Rretrograde",[166,96,61],"2025-03-12",{"date":170,"type":32},"2025-03-13",{"date":172,"type":32},"2024-04-01",{"date":174,"type":21},"2026-03-01",{"name":130,"class":74},2,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":5},"100340543","phase-3-comparative-effectiveness-between-indomethacin-and-pancreatic-stenting-in-the-prevention-of-post-ercp-pancreatitis-100340543","NCT03713879","Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis","Comparative Effectiveness Between Rectally Administered Indomethacin and Pancreatic Stenting in the Prevention of Post Endoscopic Retrograde Cholangio-panceaticography (ERCP) Pancreatitis: a Randomized Trial","Inclusion Criteria:\n\npresence of one of the following risk factors for Post ERCP Pancreatitis\n\n1. sphincter of Oddi dysfunction\n2. history of PEP, pancreatic instrumentation or sphincterotomy, precut sphincterotomy,\n3. difficult cannulation defined by \\>5 cannulation attempts\n4. the use of double wire technique in bile duct access\n5. at least 2 of the followings including i) female age\\\u003C50 ii) 3 pancreatograms iii) acinarization (contrast injection to tail fo pancreas). iv） normal bilirubin； v）guidewire to the tail of pancreas or secondary branches.\n\nExclusion Criteria:\n\n* patients intended for pancreatic stenting e.g. those with pancreatic duct strictures, ampullectomy,\n* without informed consents from patient or next of kin\n* age \\\u003C18\n* pregnant or lactating women\n* patients with altered anatomy except except Billroth I and II gastrectomy\n* contraindications to the use of NSAIDs such as those with active gastrointestinal bleeding, renal failure (serum creatinine \\> 140)\n* known NSAID allergy\n* incipient heart failure.","99 Years",{"count":186,"type":21},1734,[188],"PHASE3","Post ERCP pancreatitis (PEP) occurs in 4 to 5% of patients and is associated with significant morbidities and occasional mortalities. The use of rectall administered indomethacin and pancreatic duct stent (PDS) placement have independently been proven to reduce PEP. The comparative effectiveness of the two methods has however not been studied. It is argued that in the context of indomethacin, the placement of a PDS is unnecessary. Advocates for PDS insertion however believe that mechanical decompression of the pancreatic duct is critical in the prevention of pancreatitis. The investigators propose a multi-centre randomised controlled trial to compare the use of rectal indomethacin to PDS insertion in high risk patients in the prevention of PEP.",[27],[192,193,194],"post ERCP panceatitis","rectal indomethacin","pancreatic stents","2025-02-10",{"date":197,"type":32},"2025-02-12",{"date":199,"type":32},"2019-03-21",{"date":201,"type":21},"2026-12-31",{"name":203,"class":74},"Chinese University of Hong Kong"]